Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT06420297 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT06420297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06420297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
March 11, 2024
Completion date
December 19, 2025
Enrollment
168 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphagia in prader-willi syndrome